David Solomon - Articles and news items

zealand pharma

Zealand advances danegaptide into a Phase II clinical proof-of-concept study for protection against reperfusion injury

Industry news / 20 November 2013 / Zealand Pharma

Zealand Pharma A/S announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide…

Zealand Pharma Receives Milestone Payment from Helsinn Healthcare

Industry news, News / 9 December 2010 / M:Communications

Zealand Pharma, today announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+